Detection of exosomal miRNAs in the plasma of melanoma patients

Susan R. Pfeffer, Kenneth F. Grossmann, Pamela B. Cassidy, Chuan He Yang, Meiyun Fan, Levy Kopelovich, Sancy A. Leachman, Lawrence M. Pfeffer

Research output: Contribution to journalArticle

Abstract

MicroRNAs (miRNAs) are a class of 22–25 nucleotide RNAs that control gene expression at the post-transcriptional level. MiRNAs have potential as cancer biomarkers. Melanoma is a highly aggressive form of skin cancer accounting for almost 4% of cancers among men and women, and ~80% of skin cancer-related deaths in the US. In the present study we analyzed plasma-derived exosomal miRNAs from clinically affected and unaffected familial melanoma patients (CDKN2A/p16 gene carriers) and compared them with affected (nonfamilial melanoma) and unaffected control subjects in order to identify novel risk biomarkers for melanoma. Intact miRNAs can be isolated from the circulation because of their presence in exosomes. A number of differentially regulated miRNAs identified by NanoString human V2 miRNA array were validated by quantitative PCR. Significantly, miR-17, miR-19a, miR-21, miR-126, and miR-149 were expressed at higher levels in patients with metastatic sporadic melanoma as compared with familial melanoma patients or unaffected control subjects. Surprisingly, no substantial differences in miRNA expression were detected between familial melanoma patients (all inclusive) and unaffected control subjects. The miRNAs differentially expressed in the different patient cohorts, especially in patients with metastatic melanoma, may play important roles in tumor progression and metastasis, and may be used as predictive biomarkers to monitor remission as well as relapse following therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)2012-2027
Number of pages16
JournalJournal of Clinical Medicine
Volume4
Issue number12
DOIs
StatePublished - Dec 17 2015

Fingerprint

MicroRNAs
Melanoma
p16 Genes
Skin Neoplasms
Biomarkers
Exosomes
Tumor Biomarkers
Neoplasms
Nucleotides
RNA
Neoplasm Metastasis
Gene Expression
Recurrence
Polymerase Chain Reaction
Cutaneous Malignant Melanoma

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Detection of exosomal miRNAs in the plasma of melanoma patients. / Pfeffer, Susan R.; Grossmann, Kenneth F.; Cassidy, Pamela B.; Yang, Chuan He; Fan, Meiyun; Kopelovich, Levy; Leachman, Sancy A.; Pfeffer, Lawrence M.

In: Journal of Clinical Medicine, Vol. 4, No. 12, 17.12.2015, p. 2012-2027.

Research output: Contribution to journalArticle

Pfeffer, SR, Grossmann, KF, Cassidy, PB, Yang, CH, Fan, M, Kopelovich, L, Leachman, SA & Pfeffer, LM 2015, 'Detection of exosomal miRNAs in the plasma of melanoma patients', Journal of Clinical Medicine, vol. 4, no. 12, pp. 2012-2027. https://doi.org/10.3390/jcm4121957
Pfeffer, Susan R. ; Grossmann, Kenneth F. ; Cassidy, Pamela B. ; Yang, Chuan He ; Fan, Meiyun ; Kopelovich, Levy ; Leachman, Sancy A. ; Pfeffer, Lawrence M. / Detection of exosomal miRNAs in the plasma of melanoma patients. In: Journal of Clinical Medicine. 2015 ; Vol. 4, No. 12. pp. 2012-2027.
@article{e9ad49de8d224b9f9359e36f613609e0,
title = "Detection of exosomal miRNAs in the plasma of melanoma patients",
abstract = "MicroRNAs (miRNAs) are a class of 22–25 nucleotide RNAs that control gene expression at the post-transcriptional level. MiRNAs have potential as cancer biomarkers. Melanoma is a highly aggressive form of skin cancer accounting for almost 4{\%} of cancers among men and women, and ~80{\%} of skin cancer-related deaths in the US. In the present study we analyzed plasma-derived exosomal miRNAs from clinically affected and unaffected familial melanoma patients (CDKN2A/p16 gene carriers) and compared them with affected (nonfamilial melanoma) and unaffected control subjects in order to identify novel risk biomarkers for melanoma. Intact miRNAs can be isolated from the circulation because of their presence in exosomes. A number of differentially regulated miRNAs identified by NanoString human V2 miRNA array were validated by quantitative PCR. Significantly, miR-17, miR-19a, miR-21, miR-126, and miR-149 were expressed at higher levels in patients with metastatic sporadic melanoma as compared with familial melanoma patients or unaffected control subjects. Surprisingly, no substantial differences in miRNA expression were detected between familial melanoma patients (all inclusive) and unaffected control subjects. The miRNAs differentially expressed in the different patient cohorts, especially in patients with metastatic melanoma, may play important roles in tumor progression and metastasis, and may be used as predictive biomarkers to monitor remission as well as relapse following therapeutic intervention.",
author = "Pfeffer, {Susan R.} and Grossmann, {Kenneth F.} and Cassidy, {Pamela B.} and Yang, {Chuan He} and Meiyun Fan and Levy Kopelovich and Leachman, {Sancy A.} and Pfeffer, {Lawrence M.}",
year = "2015",
month = "12",
day = "17",
doi = "10.3390/jcm4121957",
language = "English (US)",
volume = "4",
pages = "2012--2027",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
publisher = "MDPI AG",
number = "12",

}

TY - JOUR

T1 - Detection of exosomal miRNAs in the plasma of melanoma patients

AU - Pfeffer, Susan R.

AU - Grossmann, Kenneth F.

AU - Cassidy, Pamela B.

AU - Yang, Chuan He

AU - Fan, Meiyun

AU - Kopelovich, Levy

AU - Leachman, Sancy A.

AU - Pfeffer, Lawrence M.

PY - 2015/12/17

Y1 - 2015/12/17

N2 - MicroRNAs (miRNAs) are a class of 22–25 nucleotide RNAs that control gene expression at the post-transcriptional level. MiRNAs have potential as cancer biomarkers. Melanoma is a highly aggressive form of skin cancer accounting for almost 4% of cancers among men and women, and ~80% of skin cancer-related deaths in the US. In the present study we analyzed plasma-derived exosomal miRNAs from clinically affected and unaffected familial melanoma patients (CDKN2A/p16 gene carriers) and compared them with affected (nonfamilial melanoma) and unaffected control subjects in order to identify novel risk biomarkers for melanoma. Intact miRNAs can be isolated from the circulation because of their presence in exosomes. A number of differentially regulated miRNAs identified by NanoString human V2 miRNA array were validated by quantitative PCR. Significantly, miR-17, miR-19a, miR-21, miR-126, and miR-149 were expressed at higher levels in patients with metastatic sporadic melanoma as compared with familial melanoma patients or unaffected control subjects. Surprisingly, no substantial differences in miRNA expression were detected between familial melanoma patients (all inclusive) and unaffected control subjects. The miRNAs differentially expressed in the different patient cohorts, especially in patients with metastatic melanoma, may play important roles in tumor progression and metastasis, and may be used as predictive biomarkers to monitor remission as well as relapse following therapeutic intervention.

AB - MicroRNAs (miRNAs) are a class of 22–25 nucleotide RNAs that control gene expression at the post-transcriptional level. MiRNAs have potential as cancer biomarkers. Melanoma is a highly aggressive form of skin cancer accounting for almost 4% of cancers among men and women, and ~80% of skin cancer-related deaths in the US. In the present study we analyzed plasma-derived exosomal miRNAs from clinically affected and unaffected familial melanoma patients (CDKN2A/p16 gene carriers) and compared them with affected (nonfamilial melanoma) and unaffected control subjects in order to identify novel risk biomarkers for melanoma. Intact miRNAs can be isolated from the circulation because of their presence in exosomes. A number of differentially regulated miRNAs identified by NanoString human V2 miRNA array were validated by quantitative PCR. Significantly, miR-17, miR-19a, miR-21, miR-126, and miR-149 were expressed at higher levels in patients with metastatic sporadic melanoma as compared with familial melanoma patients or unaffected control subjects. Surprisingly, no substantial differences in miRNA expression were detected between familial melanoma patients (all inclusive) and unaffected control subjects. The miRNAs differentially expressed in the different patient cohorts, especially in patients with metastatic melanoma, may play important roles in tumor progression and metastasis, and may be used as predictive biomarkers to monitor remission as well as relapse following therapeutic intervention.

UR - http://www.scopus.com/inward/record.url?scp=84964493467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964493467&partnerID=8YFLogxK

U2 - 10.3390/jcm4121957

DO - 10.3390/jcm4121957

M3 - Article

VL - 4

SP - 2012

EP - 2027

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

SN - 2077-0383

IS - 12

ER -